CIK 0001796280
- Non-accelerated filer
Oric Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ORIC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 471787157
- Phone
- +1 650-388-5600
- Business address
- 240 E. GRAND AVE., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,519,090
- in 5 filings, $1.5M under 10b5-1 plans
Net −$1,519,090. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-30 | ORBIMED ADVISORS LLC Director | Sale | −27,869 | $23.93 | $667K | 2,212,571 |
| 2021-03-29 | ORBIMED ADVISORS LLC Director | Sale | −75,555 | $23.31 | $1.8M | 2,240,440 |
| 2021-03-26 | ORBIMED ADVISORS LLC Director | Sale | −27,816 | $23.88 | $664K | 2,315,995 |
| 2021-03-25 | ORBIMED ADVISORS LLC Director | Sale | −51,523 | $24.70 | $1.3M | 2,343,811 |
| 2021-03-24 | ORBIMED ADVISORS LLC Director | Sale | −32,959 | $24.80 | $817K | 2,395,334 |
| 2021-03-23 | ORBIMED ADVISORS LLC Director | Sale | −3,992 | $24.32 | $97K | 2,428,293 |
| 2021-03-22 | ORBIMED ADVISORS LLC Director | Sale | −7,673 | $26.47 | $203K | 2,432,285 |
| 2021-03-19 | ORBIMED ADVISORS LLC Director | Sale | −21,275 | $26.47 | $563K | 2,439,958 |
| 2021-03-18 | ORBIMED ADVISORS LLC Director | Sale | −6,059 | $28.03 | $170K | 2,461,233 |
| 2021-03-17 | ORBIMED ADVISORS LLC Director | Sale | −18,790 | $28.43 | $534K | 2,467,292 |
| 2021-03-16 | ORBIMED ADVISORS LLC Director | Sale | −41,353 | $27.72 | $1.1M | 2,486,082 |
| 2021-03-15 | ORBIMED ADVISORS LLC Director | Sale | −89,210 | $29.14 | $2.6M | 2,527,435 |
| 2021-03-12 | ORBIMED ADVISORS LLC Director | Sale | −90,521 | $30.29 | $2.7M | 2,616,645 |
| 2021-03-11 | ORBIMED ADVISORS LLC Director | Sale | −58,551 | $33.04 | $1.9M | 2,707,166 |
| 2020-04-28 | ORBIMED ADVISORS LLC Director | Conversion | +1,875,000 | 2,156,250 | ||
| 2020-04-28 | ORBIMED ADVISORS LLC Director | Conversion | +373,356 | 2,529,606 | ||
| 2020-04-28 | ORBIMED ADVISORS LLC Director | Conversion | +236,111 | 2,765,717 | ||
| 2020-04-28 | ORBIMED ADVISORS LLC Director | Conversion · Series B Preferred Stock | −1,875,000 | 0 | ||
| 2020-04-28 | ORBIMED ADVISORS LLC Director | Conversion · Series C Preferred Stock | −373,356 | 0 | ||
| 2020-04-28 | ORBIMED ADVISORS LLC Director | Conversion · Series D Preferred Stock | −236,111 | 0 |
Page 1 of 2 · 21 trades